Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Paediatrics

Metronomics — fulfilling unmet needs beyond level A evidence

Nature Reviews Clinical Oncology volume 13, pages 469–470 (2016)Cite this article

Subjects

To improve the survival rates globally for paediatric patients with cancer, looking beyond level A evidence to treat children in low and middle-income countries is imperative. Herein, we discuss why metronomic chemotherapy, which is less toxic and more affordable, offers a pragmatic approach to provide new standards for patients with relapsed disease who have no alternatives.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Magrath, I. et al. Paediatric cancer in low-income and middle-income countries. Lancet Oncol. 14, e104–e116 (2013).

    Article  Google Scholar 

  2. Rodriguez-Galindo, C. et al. Toward the cure of all children with cancer through collaborative efforts: pediatric oncology as a global challenge. J. Clin. Oncol. 33, 3065–3073 (2015).

    Article  CAS  Google Scholar 

  3. Prowell, T. M., Theoret, M. R. & Pazdur, R. Seamless oncology-drug development. N. Engl. J. Med. 374, 2001–2003 (2016).

    Article  Google Scholar 

  4. Kahalley, L. S. et al. Comparing intelligence quotient change after treatment with proton versus photon radiation therapy for pediatric brain tumors. J. Clin. Oncol. 34, 1043–1049 (2016).

    Article  CAS  Google Scholar 

  5. Le Tourneau, C. et al. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open- label, proof-of-concept, randomised, controlled phase 2 trial. Lancet Oncol. 16, 1324–1334 (2015).

    Article  CAS  Google Scholar 

  6. Arora, R. S., Challinor, J. M., Howard, S. C. & Israels, T. Improving care for children with cancer in low- and middle-income countries — a SIOP PODC initiative. Pediatr. Blood Cancer 63, 387–391 (2016).

    Article  Google Scholar 

  7. Brugières, L. et al. Single-drug vinblastine as salvage treatment for refractory or relapsed anaplastic large-cell lymphoma: a report from the French Society of Pediatric Oncology. J. Clin. Oncol. 27, 5056–5061 (2009).

    Article  Google Scholar 

  8. Lakshmaiah, K. C. et al. Anaplastic large cell lymphoma: a single institution experience from India. J. Cancer Res. Ther. 9, 649–652 (2013).

    Article  CAS  Google Scholar 

  9. André, N. et al. Maintenance chemotherapy in children with ALL exerts metronomic-like thrombospondin-1 associated anti-endothelial effect. Oncotarget 6, 23008–23014 (2015).

    Article  Google Scholar 

  10. André, N., Banavali, S., Snihur, Y. & Pasquier, E. Has the time come for metronomics in low-income and middle-income countries? Lancet Oncol. 14, e239–e248 (2013).

    Article  Google Scholar 

  11. André, N., Carré, M. & Pasquier, E. Metronomics: towards personalized chemotherapy? Nat. Rev. Clin. Oncol. 11, 413–431 (2014).

    Article  Google Scholar 

  12. Fousseyni, T., Diawara, M., Pasquier, E. & André, N. Children treated with metronomic chemotherapy in a low income country: METRO-MALI-01. J. Pediatr. Hematol. Oncol. 33, 31–34 (2011).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Nicolas André is at Inserm UMR_S 911, Centre de Recherche en Oncologie biologique et Oncopharmacologie, 27 Boulevard Jean Moulin, Faculté de Pharmacie, Aix-Marseille Université; and the Metronomics Global Health Initiative, 13005 Marseille, France.,

    Nicolas André

  2. Service d'Hématologie & Oncologie Pédiatrique, AP-HM,

    Nicolas André

  3. Shripad Banavali is at the Department of Medical Oncology, Tata Memorial Centre, Dr. E Borges Road, 400012, Parel, Mumbai, India,

    Shripad Banavali

  4. the Metronomics Global Health Initiative, 13005 Marseille, France,

    Shripad Banavali

  5. Eddy Pasquier is at Inserm UMR_S 911, Centre de Recherche en Oncologie biologique et Oncopharmacologie, 27 Boulevard Jean Moulin, Faculté de Pharmacie, Aix-Marseille Université,

    Eddy Pasquier

  6. the Metronomics Global Health Initiative, 13005 Marseille, France.,

    Eddy Pasquier

Authors
  1. Nicolas André
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shripad Banavali
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Eddy Pasquier
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nicolas André.

Ethics declarations

Competing interests

N.A. is consultant for Sanofi and receives travel grants and honoraria from Pierre Fabre Oncology. E.P. receives honoraria from Pierre Fabre. S.B. declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

André, N., Banavali, S. & Pasquier, E. Metronomics — fulfilling unmet needs beyond level A evidence. Nat Rev Clin Oncol 13, 469–470 (2016). https://doi.org/10.1038/nrclinonc.2016.102

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrclinonc.2016.102

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer